Public Meeting on Patient-Focused Drug Development for Sarcopenia
On April 6, 2017, FDA is conducting a public meeting on Patient-Focused Drug Development (PFDD) for Sarcopenia. FDA is interested in obtaining patient perspectives on the on the impact of sarcopenia on daily life and patient views on treatment approaches.
April 6, 2017
1:00 p.m. - 5:00 p.m.
Tommy Douglas Conference Center
10000 New Hampshire Ave.
Silver Spring, MD 20903
To register for this meeting, visit: Patient-Focused Drug Development Public Meeting for Sarcopenia Event Brite website.
Registration to attend the meeting must be received by April 6, 2017.
In addition to providing input at the public meeting, stakeholders are invited to provide their perspectives on the discussion questions through the public docket. The docket closes on June 6, 2017.
- Meeting Agenda
- Meeting Slides
- Federal Register
- The Voice of the Patient: Sarcopenia
- Webinar: Background on FDA and Patient-Focused Drug Development
- Meeting Recording
- Meeting Transcript: Thursday, April 6, 2017